

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Raptor Pharmaceutical Corp
Form 8-K
November 15, 2012
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2012

RAPTOR PHARMACEUTICAL CORP.

(Exact name of registrant as specified in its charter)

Delaware 000-25571 86-0883978
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

9 Commercial Blvd., Suite 200, Novato, California 94949
(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (415) 382-8111

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02 Results of Operations and Financial Condition.

On November 14, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release reporting its financial results for its fourth quarter and fiscal year ended August 31, 2012. A copy of the press release is being furnished as Exhibit 99.1 and is incorporated herein by reference.

The information included in this Item 2.02 of this Current Report on Form 8-K, including the information incorporated by reference in the exhibit hereto, shall not be deemed "filed" for purposes of, nor shall it be deemed incorporated by reference in, any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Exhibit Description	Filed Here Incorporated by Reference with Form	File No.	Exhibit	Filing Date	Filed By
99.1	Press release issued by the Company dated as of November 14, 2012	X				

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR
PHARMACEUTICAL CORP.

Date: November 14, 2012 By: /s/ Kim R. Tsuchimoto
Name: Kim R. Tsuchimoto
Title: Vice President, Finance

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Exhibit Index

Exhibit		Filed	Here Incorporated by Reference	
No.	Exhibit Description	with Form	File No. Exhibit	Filing Date
				Filed By
99.1	Press release issued by the Company dated as of November 14, 2012		X	